We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Celgene Ordered To Turn Over Thalomid Price Data

Law360 (January 20, 2011, 7:15 PM EST) -- New Jersey-based drugmaker Celgene Corp. must turn over pricing data on its drug Thalomid to Canadian authorities so they can determine if patients are being gouged, Canada's high court ruled Thursday.

The country's Patented Medicine Prices Review Board has jurisdiction to regulate Thalomid prices, even though the drug is not sold directly to Canadian consumers, the Supreme Court of Canada said in a unanimous decision.

Thalomid is a version of the sedative thalidomide used to treat conditions such as leprosy and multiple myeloma, a type of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.